The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients

Annals of Hematology

Volumn 91, Issue 9, 2012, Pages 1333-1343

  Stauder, Reinhard ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Assessment; Elderly; Geriatric; Myelodysplastic syndromes (MDS); Therapy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE; AZACITIDINE; CLOFARABINE; CYTARABINE; DNA METHYLTRANSFERASE INHIBITOR; GRANULOCYTE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; ITRACONAZOLE; LENALIDOMIDE; LIDAPRIM; PROTEIN TYROSINE KINASE INHIBITOR; SAPACITABINE; TROPISETRON; VALACICLOVIR; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; AGRANULOCYTOSIS; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CYTOPENIA; DAILY LIFE ACTIVITY; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; ERYTHROCYTE TRANSFUSION; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HUMAN; INFECTION; INJECTION SITE REACTION; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; IRON CHELATION; IRON OVERLOAD; LIFE EXPECTANCY; LOW DRUG DOSE; MULTIDIMENSIONAL GERIATRIC ASSESSMENT; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; REFRACTORY ANEMIA WITH EXCESS BLASTS; RISK ASSESSMENT; SCORING SYSTEM; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT PLANNING;

AGED; AGED, 80 AND OVER; ALGORITHMS; ANTINEOPLASTIC AGENTS; AZACITIDINE; CASE MANAGEMENT; COMORBIDITY; DECISION SUPPORT SYSTEMS, CLINICAL; DNA METHYLATION; FEMALE; FRAIL ELDERLY; HUMANS; INDIVIDUALIZED MEDICINE; LIFE EXPECTANCY; MALE; MYELODYSPLASTIC SYNDROMES; PALLIATIVE CARE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84864911973     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1472-8     Document Type: Article

References (66)

1. Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ et al (2011) Myelodysplastic syndromes. J Natl Compr Canc Netw 9(1):30-56
2. Germing U, Aul C, Niemeyer CM, Haas R, Bennett JM (2008) Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. Ann Hematol 87(9):691-699
3. Balducci L, Extermann M (2000) Management of cancer in the older person: a practical approach. Oncologist 5(3):224-237
4. Balducci L (2007) Aging, frailty, and chemotherapy. Cancer Control 14(1):7-12
5. Extermann M, Hurria A (2007) Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 10(14):1824-1831
6. Arking R (2006) The biology of aging: observations and principles, 3rd edn. Oxford University Press, New York
7. Mahoney FI, Barthel DW (1965) Functional evaluation: the Barthel Index. Md State Med J 14:61-65
8. Lawton MP, Brody EM (1969) Assessment of older people: selfmaintaining and instrumental activities of daily living. Gerontologist 9(3):179-186
9. Stauder R, Noesslinger TH, Pfeilstöcker M, Sperr WR, Wimazal F, Krieger O et al (2008) Impact of age and comorbidity in myelodysplastic syndromes. J Natl Compr Canc Netw 6(9):927-934
10. Naqvi K, Garcia-Manero G, Sardesai S, Oh J, Vigil CE, Pierce S et al (2011) Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol 29(16):2240-2246
11. Inouye SK, Studenski S, Tinetti ME, Kuchel GA (2007) Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc 55(5):780-791
12. Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP et al (2011) Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 29(25):3457-3465
13. ExtermannM, Boler I, Reich RR, Lyman GH, Brown RH, Defelice J et al (2011) Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. doi:10.1002/cncr.26646
14. Gosney M (2007) Contribution of the geriatrician to the management of cancer in older patients. Eur J Cancer 43(15):2153-2160
15. Gosney MA (2005) Clinical assessment of elderly people with cancer. Lancet Oncol 6:790-797
16. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341(27):2061-2067
17. Extermann M, Albrand G, Chen H, Zanetta S, Schonwetter R, Zulian GB et al (2003) Are older French patients as willing as older American patients to undertake chemotherapy? J Clin Oncol 21(17):3214-3219
18. Hurria A, Browner IS, Cohen HJ, Denlinger CS, deShazo M, Extermann M et al. NCCN clinical practical guidelines in oncology: senior adult oncology, version 1.2011 Available from: http:// www.nccn.org/professionals/physician-gls/ pdf/senior.pdf. Accessed 4 Apr 2011
19. Stauder R, Wimazal F, Nösslinger T, Krieger O, Sperr WR, Sill H et al (2008) Individualized management and therapy of myelodysplastic syndromes. Wien Klin Wochenschr 120(17-18):523-537
20. Deschler B, de Witte T, Mertelsmann R, Lübbert M (2006) Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 91(11):1513-1522
21. Ria R, Moschetta M, Reale A, Mangialardi G, Castrovilli A, Vacca A et al (2009) Managing myelodysplastic symptoms in elderly patients. Clin Interv Aging 4:413-423
22. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51(2):189-199
23. Bruning RD, Orazi A, Germing U, Le Beau MM, Porwit A, Baumann I et al (2008) Myelodyspalstic syndromes. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) World Health Organization classification of tumours of the hematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, Lyon
24. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6):2079-2088
25. Malcovati L, Porta M, Pascutto C, Invernizzi R, Boni M, Travaglino E et al (2005) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria, a basis for clinical decision making. J Clin Oncol 23(30):7594-7603
26. Sperr WR, Wimazal F, Kundi M, Baumgartner C, Nösslinger T, Makrai A et al (2010) Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol 21 (1):114-119
27. Valent P, Krieger O, Stauder R, Wimazal F, Nösslinger T, Sperr WR et al (2008) Iron overload in myelodysplastic syndromes (MDS)-diagnosis, management, and response criteria: a proposal of the Austrian MDS platform. Eur J Clin Invest 38(3):143-149
28. Giagounidis A, Leto di Priolo S, Ille S, Fenaux P (2011) A European survey on the detection and management of iron overload in transfusion-dependent patients with MDS. Ann Hematol 90 (6):667-673
29. Nachtkamp K, Kündgen A, Strupp C, Giagounidis A, Kobbe G, Gattermann N et al (2009) Impact on survival of different treatments for myelodysplastic syndromes (MDS). Leuk Res 33 (8):1024-1028
30. Parmara S, de Limaa M, Deegb HJ (2011) Champlin R Hematopoietic stem cell transplantation for myelodysplastic syndrome: a review. Semin Oncol 38(5):693-704
31. de Witte T (2011) Allogeneic stem cell transplantation for myelodysplastic syndromes: critical for cure? Clin Lymphoma Myeloma Leuk 11(Suppl 1):S46-S48
32. Deschler B, Binek K, Ihorst G, Marks R, Wäsch R, Bertz H et al (2010) Prognostic factor and quality of life analysis in 160 patients aged or 060 years with hematologic neoplasias treated with allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 16(7):967-975
33. McClune BL, Weisdorf DJ, Pedersen TL, TunesdaSilva G, Tallman MS, Sierra J et al (2010) Effect of age on outcome of reducedintensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 28(11):1878-1887
34. Chevallier P, Szydlo RM, Blaise D, Tabrizi R, Michallet M, Uzunov M et al (2012) Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC. Biol Blood Marrow Transplant 18(2):289-294
35. Bokhari SW, Watson L, Nagra S, Cook M, Byrne JL, Craddock C et al (2011) Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reducedintensity- conditioning hemopoeitic progenitor cell transplantation. Bone Marrow Transplant. doi:10.1038/bmt.2011.138
36. Garcia-Manero G, Fenaux P (2011) Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol 29(5):516-523
37. Celgene Corporation, 07/2010. Vidaza® (azacitidine) EU prescribing information. Available from: http://www.ema.europa.eu/docs/ en-GB/document- library/EPAR-Product-Information/human/ 000978/WC500050239.pdf. Accessed 28 Jan 2012
38. Celgene Corporation, 08/2008. Vidaza® (azacitidine) US prescribing information. Available from: http://www.vidaza.com/pdf/ PI-FINAL.pdf. Accessed 28 Jan 2012
39. Dacogen® (decitabine) US prescribing information. Available from: http://www.dacogen.com/PI.aspx. Accessed 4 Apr 2011
40. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10(3):223-232
41. Seymour JF, Fenaux P, Silverman LR, Mufti GJ, Hellström- Lindberg E, Santini Vet al (2010) Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 76(3):218-227
42. Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U et al (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28(4):562-569
43. Fenaux P, Gattermann N, Seymour JF, Hellström-Lindberg E, Mufti GJ, Duehrsen U et al (2010) Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol 149(2):244-249
44. Itzykson R, Thépot S, Quesnel B, Dreyfus E, Beyne-Ranzyl O, Turlure P et al (2011) Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 117(2):403-411
45. Itzykson R, Thépot S, Achour B, Quesnel B, Dreyfus F, Turlure P, et al (2009) Azacytidine (AZA) in MDS (including RAEB-t and CMML) in patients (pts)≥80 years: results of the French ATU Program. Blood 114: abstract 1773
46. Fenaux P, Bowen D, Gattermann N, Hellström-Lindberg E, Hofmann WK, Pfeilstöcker M et al (2010) Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion. Leuk Res 34(11):1410-1416
47. Seymour JF, Santini V, Fenaux P,Giagounidis AAN, Sanz GF, Finelli C, et al (2010) Achievement of red blood cell (RBC) transfusion independence with azacitidine (AZA) leads to improved survival in patients with higher-risk myelodysplasias regardless of baseline transfusion needs. Blood 116: abstract 1856
48. Kornblith AB, Herndon JE 2nd, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF et al (2002) Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a cancer and leukemia group B study. J Clin Oncol 20(19):2441-2452
49. Santini V, Fenaux P, Mufti GJ, Hellström-Lindberg E, Silverman LR, List A et al (2010) Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol 85(2):130-138
50. Götze K, Platzbecker U, Giagounidis A, Haase D, Lübbert M, Aul C et al (2010) Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group. Ann Hematol 89(9):841-850
51. Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A et al (2011) Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 29(15):1987-1996
52. Kantarjian HM, O'Brien S, Huang X, Garcia-Manero G, Ravandi F, Cortes J et al (2007) Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 109 (6):1133-1137
53. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J et al (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106(8):1794-1803
54. Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G et al (2009) Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 27(23):3842-3848
55. Garcia-Manero G, Gore SD, Cogle C, Ward R, Shi T, Macbeth KJ et al (2011) Phase I study of oral azacitidine inmyelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol 29(18):2521-2527
56. Adès L, Boehrer S, Prebet T, Beyne-Rauzy O, Legros L, Ravoet C et al (2009) Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood 113(17):3947-3952
57. Cololar® (clofarabine) US prescribing information 2008. Available from: http://www.genzymeoncology.com/pdf/Clolar-Full-Pl.pdf. Accessed 28 Jan 2012
58. Evoltra® (clofarabine) EU prescribing information 12/2011. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product- Information/human/000613/WC500031191.pdf. Accessed 28 Jan 2012
59. Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T, Gabrilove J, CraigM, Douer D, MarisM, Petersdorf S, Shami PJ, Yeager AM, Eckert S, Abichandani R, Faderl S (2010) Phase II study of clofarabine monotherapy in previously untreated older adults with acutemyeloid leukemia and unfavorable prognostic factors. J Clin Oncol 28(4):549-555
60. Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Borthakur G, Cortes JE, O'Brien S, Gandhi V, Plunkett W, Byrd A, Kwari M, Kantarjian HM (2010) Oral clofarabine in the treatment of patients with higherrisk myelodysplastic syndrome. J Clin Oncol 28(16):2755-2760
61. Faderl S, Garcia-Manero G, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Gandhi V, Byrd AL, Kwari M, Cortes J, Kantarjian HM (2012) A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer 118(3):722-728
62. Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Westwood R, Green SR, Chiao JH, Boone PA, Cortes J, Plunkett W (2010) Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol 28(2):285-291
63. Ravandi F, Faderl S, Cortes JE, Garcia-Manero G, Jabbour E, Boone PA, Kadia T, Borthakur G, Wierda WG, Wetzler M, Venugopal P, Chiao J, Kantarjian HM (2011) Phase 1/ 2 study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed AML. Blood (ASH Annual Meeting Abstracts), November, vol. 118, p. 3630
64. Stauder R,Moser K, Holzner B, Sperner-Unterweger B, Kemmler G (2010) Six independent domains are defined by geriatric assessment in elderly cancer patients. Crit Rev Oncol Hematol 74:97-105
65. Valentiny C, Kemmler G, Stauder R (2012) Age, sex and gender impact multidimensional geriatric assessment in elderly cancer patients. J Geriatr Oncol 3:17-23
66. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT et al (2006) International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWGMRT). Blood 108(5):1497-1503